Skip to content

Eczema relief through honey: Exploring advantages and application methods

Benefits and Usage of Honey for Eczema Management

Eczema Treatment with Honey: Exploring Its Advantages and Usage Methods
Eczema Treatment with Honey: Exploring Its Advantages and Usage Methods

Eczema relief through honey: Exploring advantages and application methods

Manuka honey, a unique type of honey produced in New Zealand, has gained recognition worldwide for its therapeutic properties when it comes to treating various skin conditions, particularly eczema.

This honey is rich in Methylglyoxal (MGO), a compound responsible for its potent antibacterial activity. This antibacterial boost specifically targets Staphylococcus aureus, a common trigger for eczema flare-ups and infections. Laboratory studies confirm the ability of Manuka honey's active components to inhibit S. aureus, reducing infection risks on compromised skin.

In addition to its antibacterial effects, Manuka honey and its oil reduce inflammation by down-regulating pro-inflammatory cytokines, easing redness and swelling associated with eczema. This anti-inflammatory action contributes to calming irritated skin and improving symptoms.

Clinically, formulations containing high MGO Manuka honey have been dermatologist-tested to soothe, moisturize, and protect dry and fragile skin affected by eczema and related conditions such as psoriasis and rosacea. The honey also promotes tissue regeneration and creates an environment conducive to skin healing.

Manuka oil, often used alongside Manuka honey, enhances these benefits by accelerating wound healing processes such as re-epithelialization and collagen deposition, which can also aid in skin barrier repair in eczema.

In summary, Manuka honey's combination of antibacterial (especially against S. aureus), anti-inflammatory, and tissue-healing effects make it a promising natural adjunct in managing atopic dermatitis, especially in cases complicated by bacterial infection or skin barrier impairment.

Key points: - The MGO concentration in Manuka honey is crucial to its effectiveness; higher MGO levels (e.g., 600+) provide stronger antibacterial action. - Antibacterial action targets S. aureus, often involved in eczema infections. - Anti-inflammatory effects reduce redness and swelling via cytokine modulation. - Supports skin healing and regeneration, improving barrier function. - Products vary, but those tested and certified for MGO content offer the most reliable results.

Therefore, topical application of validated Manuka honey products can be an effective supportive treatment for eczema by combatting infection and inflammation while promoting skin repair. However, it is essential to consult a healthcare professional before using honey to treat eczema, especially for severe cases.

  1. The antibacterial properties of Manuka honey, as demonstrated by its high Methylglyoxal (MGO) content, specifically targets Staphylococcus aureus, a common eczema trigger, contributing to infection reduction on compromised skin.
  2. In addition to its antibacterial effects, Manuka honey and its oil exhibit anti-inflammatory properties by down-regulating pro-inflammatory cytokines, thereby reducing redness and swelling associated with eczema and soothing irritated skin.
  3. Manuka oil, coupled with Manuka honey, enhances wound healing processes in eczema, promoting re-epithelialization, collagen deposition, and skin barrier repair.
  4. Topical application of validated Manuka honey products, specifically those certified for MGO content, can be an effective supportive treatment for eczema by combatting infection, inflammation, and promoting skin repair, though consulting a healthcare professional is crucial for severe cases.

Read also:

    Latest

    FDA accepts New Drug Application from Arvinas for Vepdegestrant, a potential treatment for...

    Agency Arvinas announces Federal Drug Administration acceptance of Vepdegestrant's New Drug Application for tackling ESR1m-positive, ER+/HER2- advanced breast cancer treatment.

    Vepdegestrant, a PROTAC drug, shows promising results in Phase 3 VERITAC-2 clinical trial, providing statistically significant and clinically relevant improvement in median progression-free survival compared to fulvestrant, becoming the first PROTAC to show clinical benefits...